Mahasweta Gooptu, M.B.,B.S.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Graft vs Host Disease | 24 | 2024 | 2957 | 3.900 |
Why?
|
Hematopoietic Stem Cell Transplantation | 32 | 2023 | 5442 | 3.050 |
Why?
|
Transplantation Conditioning | 8 | 2024 | 1598 | 1.240 |
Why?
|
Cyclophosphamide | 7 | 2023 | 2242 | 1.140 |
Why?
|
Tacrolimus | 4 | 2023 | 743 | 1.070 |
Why?
|
Transplantation, Homologous | 11 | 2024 | 4776 | 1.020 |
Why?
|
Myelodysplastic Syndromes | 4 | 2022 | 1352 | 0.910 |
Why?
|
Opportunistic Infections | 1 | 2023 | 389 | 0.750 |
Why?
|
Leukemia, Myeloid, Acute | 8 | 2024 | 3523 | 0.740 |
Why?
|
Lymphohistiocytosis, Hemophagocytic | 1 | 2023 | 260 | 0.700 |
Why?
|
Hematologic Neoplasms | 3 | 2023 | 1832 | 0.670 |
Why?
|
Epstein-Barr Virus Infections | 1 | 2023 | 570 | 0.600 |
Why?
|
Cytomegalovirus Infections | 1 | 2023 | 820 | 0.580 |
Why?
|
Antilymphocyte Serum | 1 | 2018 | 492 | 0.570 |
Why?
|
Oxidative Phosphorylation | 1 | 2017 | 481 | 0.520 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 3 | 2021 | 1378 | 0.490 |
Why?
|
Glycolysis | 1 | 2017 | 827 | 0.460 |
Why?
|
Lymphoma, T-Cell, Peripheral | 1 | 2015 | 134 | 0.440 |
Why?
|
Sirolimus | 1 | 2019 | 1564 | 0.410 |
Why?
|
Immunosuppressive Agents | 2 | 2021 | 4149 | 0.380 |
Why?
|
Recovery of Function | 1 | 2019 | 2925 | 0.330 |
Why?
|
Recurrence | 6 | 2023 | 8340 | 0.260 |
Why?
|
Mitochondria | 1 | 2017 | 3520 | 0.240 |
Why?
|
Activated-Leukocyte Cell Adhesion Molecule | 1 | 2022 | 22 | 0.220 |
Why?
|
Interleukin-2 | 2 | 2022 | 1904 | 0.200 |
Why?
|
Busulfan | 2 | 2021 | 263 | 0.200 |
Why?
|
Vidarabine | 2 | 2021 | 345 | 0.190 |
Why?
|
Adult | 23 | 2023 | 214055 | 0.190 |
Why?
|
Humans | 45 | 2024 | 744343 | 0.180 |
Why?
|
Acute Disease | 3 | 2020 | 7149 | 0.180 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 2 | 2021 | 1596 | 0.180 |
Why?
|
Hepatic Veno-Occlusive Disease | 1 | 2022 | 220 | 0.180 |
Why?
|
BK Virus | 1 | 2020 | 129 | 0.170 |
Why?
|
Transplantation Immunology | 1 | 2021 | 546 | 0.170 |
Why?
|
Herpesvirus 4, Human | 1 | 2023 | 1041 | 0.160 |
Why?
|
Monocarboxylic Acid Transporters | 1 | 2017 | 80 | 0.150 |
Why?
|
Myeloablative Agonists | 1 | 2018 | 218 | 0.150 |
Why?
|
Whole-Body Irradiation | 1 | 2018 | 449 | 0.150 |
Why?
|
Standard of Care | 1 | 2021 | 564 | 0.150 |
Why?
|
Immunocompromised Host | 2 | 2019 | 847 | 0.150 |
Why?
|
Sulfonamides | 2 | 2024 | 1938 | 0.150 |
Why?
|
Cryopreservation | 1 | 2021 | 670 | 0.140 |
Why?
|
Cytomegalovirus | 1 | 2021 | 732 | 0.140 |
Why?
|
Aminopterin | 1 | 2015 | 15 | 0.130 |
Why?
|
Disseminated Intravascular Coagulation | 1 | 2015 | 188 | 0.120 |
Why?
|
Symporters | 1 | 2017 | 362 | 0.120 |
Why?
|
Retrospective Studies | 12 | 2023 | 77449 | 0.120 |
Why?
|
Disease Susceptibility | 1 | 2021 | 1782 | 0.120 |
Why?
|
Diphtheria Toxin | 1 | 2015 | 255 | 0.120 |
Why?
|
Middle Aged | 15 | 2021 | 213383 | 0.120 |
Why?
|
Compartment Syndromes | 1 | 2015 | 153 | 0.110 |
Why?
|
Orbital Diseases | 1 | 2015 | 181 | 0.110 |
Why?
|
Lymphocyte Activation | 2 | 2022 | 5524 | 0.110 |
Why?
|
Piperidines | 1 | 2021 | 1602 | 0.110 |
Why?
|
Orbital Neoplasms | 1 | 2015 | 225 | 0.110 |
Why?
|
Hepatitis B Core Antigens | 1 | 2012 | 92 | 0.110 |
Why?
|
Radiography, Thoracic | 1 | 2019 | 1265 | 0.110 |
Why?
|
Pharmaceutical Preparations | 1 | 2021 | 1071 | 0.110 |
Why?
|
Muscle Proteins | 1 | 2017 | 1159 | 0.100 |
Why?
|
Stromal Cells | 1 | 2017 | 1355 | 0.100 |
Why?
|
Membrane Transport Proteins | 1 | 2017 | 1028 | 0.100 |
Why?
|
Azacitidine | 2 | 2024 | 347 | 0.100 |
Why?
|
Communicable Diseases | 1 | 2019 | 880 | 0.100 |
Why?
|
Saccharomyces cerevisiae | 1 | 2022 | 2752 | 0.100 |
Why?
|
Aged | 13 | 2022 | 163280 | 0.090 |
Why?
|
Acute Kidney Injury | 1 | 2023 | 1972 | 0.090 |
Why?
|
Disease Management | 1 | 2021 | 2459 | 0.090 |
Why?
|
Histone Deacetylase Inhibitors | 1 | 2015 | 789 | 0.090 |
Why?
|
Lymphocytes | 1 | 2017 | 2617 | 0.090 |
Why?
|
Hepatitis B virus | 1 | 2012 | 513 | 0.080 |
Why?
|
Male | 13 | 2021 | 350118 | 0.080 |
Why?
|
Combined Modality Therapy | 1 | 2021 | 8642 | 0.080 |
Why?
|
Lung Diseases | 1 | 2019 | 1886 | 0.080 |
Why?
|
Neoplasm Recurrence, Local | 2 | 2023 | 9239 | 0.080 |
Why?
|
Female | 13 | 2021 | 380194 | 0.080 |
Why?
|
Receptors, Cell Surface | 1 | 2017 | 2866 | 0.080 |
Why?
|
Pulmonary Embolism | 1 | 2020 | 2376 | 0.080 |
Why?
|
Immunoconjugates | 1 | 2015 | 901 | 0.070 |
Why?
|
Steroids | 2 | 2023 | 930 | 0.070 |
Why?
|
Hepatitis B | 1 | 2012 | 695 | 0.070 |
Why?
|
Recombinant Fusion Proteins | 1 | 2015 | 3772 | 0.070 |
Why?
|
Stem Cell Transplantation | 1 | 2015 | 1620 | 0.070 |
Why?
|
Antineoplastic Agents | 2 | 2022 | 13695 | 0.070 |
Why?
|
Bone Marrow Transplantation | 2 | 2023 | 2765 | 0.060 |
Why?
|
Survival Analysis | 1 | 2018 | 10252 | 0.060 |
Why?
|
Double-Blind Method | 1 | 2018 | 12026 | 0.060 |
Why?
|
Young Adult | 6 | 2021 | 56430 | 0.060 |
Why?
|
Immunohistochemistry | 1 | 2017 | 11366 | 0.060 |
Why?
|
Adolescent | 4 | 2020 | 85781 | 0.060 |
Why?
|
Hypersensitivity | 1 | 2012 | 1102 | 0.060 |
Why?
|
Child | 2 | 2023 | 77709 | 0.060 |
Why?
|
Molecular Targeted Therapy | 1 | 2015 | 2727 | 0.060 |
Why?
|
T-Lymphocytes | 1 | 2020 | 10180 | 0.050 |
Why?
|
Fetal Proteins | 1 | 2022 | 94 | 0.050 |
Why?
|
Killer Cells, Natural | 2 | 2022 | 2133 | 0.050 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2023 | 11524 | 0.050 |
Why?
|
Pandemics | 1 | 2021 | 8388 | 0.050 |
Why?
|
Mycophenolic Acid | 1 | 2023 | 343 | 0.050 |
Why?
|
Tissue Donors | 2 | 2022 | 2240 | 0.050 |
Why?
|
Cell Adhesion Molecules, Neuronal | 1 | 2022 | 265 | 0.050 |
Why?
|
Polydeoxyribonucleotides | 1 | 2022 | 127 | 0.050 |
Why?
|
Forehead | 1 | 2021 | 69 | 0.050 |
Why?
|
Ohio | 1 | 2021 | 337 | 0.050 |
Why?
|
Antigens, Differentiation, T-Lymphocyte | 1 | 2022 | 906 | 0.050 |
Why?
|
Graft vs Leukemia Effect | 1 | 2020 | 111 | 0.050 |
Why?
|
Acetates | 1 | 2021 | 311 | 0.040 |
Why?
|
Case-Control Studies | 1 | 2017 | 21746 | 0.040 |
Why?
|
Referral and Consultation | 1 | 2012 | 3528 | 0.040 |
Why?
|
Aged, 80 and over | 3 | 2020 | 57776 | 0.040 |
Why?
|
Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2022 | 903 | 0.040 |
Why?
|
Lung Diseases, Fungal | 1 | 2019 | 122 | 0.040 |
Why?
|
Protein Kinase Inhibitors | 1 | 2015 | 5535 | 0.040 |
Why?
|
Fibrin Fibrinogen Degradation Products | 1 | 2020 | 426 | 0.040 |
Why?
|
Adenocarcinoma | 1 | 2015 | 6364 | 0.040 |
Why?
|
Cohort Studies | 2 | 2018 | 40561 | 0.040 |
Why?
|
Decision Trees | 1 | 2019 | 506 | 0.040 |
Why?
|
Methotrexate | 1 | 2023 | 1727 | 0.040 |
Why?
|
Progesterone | 1 | 2021 | 776 | 0.030 |
Why?
|
Adenine | 1 | 2021 | 936 | 0.030 |
Why?
|
Pleural Effusion | 1 | 2019 | 338 | 0.030 |
Why?
|
Tomography, X-Ray Computed | 1 | 2019 | 20129 | 0.030 |
Why?
|
Transplantation, Autologous | 1 | 2021 | 2124 | 0.030 |
Why?
|
Isocitrate Dehydrogenase | 1 | 2021 | 871 | 0.030 |
Why?
|
Incidence | 2 | 2023 | 20947 | 0.030 |
Why?
|
Treatment Outcome | 1 | 2021 | 63114 | 0.030 |
Why?
|
Quinazolines | 1 | 2021 | 1356 | 0.030 |
Why?
|
Gastrointestinal Tract | 1 | 2020 | 814 | 0.030 |
Why?
|
Prostatic Neoplasms | 1 | 2015 | 11124 | 0.030 |
Why?
|
Immunotherapy, Adoptive | 1 | 2021 | 1270 | 0.030 |
Why?
|
Antigens, CD | 1 | 2022 | 4026 | 0.030 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2022 | 2948 | 0.030 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2021 | 2942 | 0.020 |
Why?
|
Hepatitis B Surface Antigens | 1 | 2012 | 305 | 0.020 |
Why?
|
Adrenal Cortex Hormones | 1 | 2020 | 1855 | 0.020 |
Why?
|
Conjunctivitis | 1 | 2012 | 158 | 0.020 |
Why?
|
Kaplan-Meier Estimate | 1 | 2021 | 6538 | 0.020 |
Why?
|
Vaccination | 1 | 2022 | 3278 | 0.020 |
Why?
|
Animals | 1 | 2021 | 168757 | 0.020 |
Why?
|
Antiviral Agents | 1 | 2021 | 2987 | 0.020 |
Why?
|
Respiratory Sounds | 1 | 2012 | 696 | 0.020 |
Why?
|
Chronic Disease | 1 | 2023 | 9146 | 0.020 |
Why?
|
Massachusetts | 1 | 2021 | 8663 | 0.020 |
Why?
|
Boston | 1 | 2020 | 9313 | 0.020 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 2020 | 4386 | 0.020 |
Why?
|
Pneumonia | 1 | 2019 | 2133 | 0.020 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2020 | 4479 | 0.020 |
Why?
|
CD4 Lymphocyte Count | 1 | 2012 | 2559 | 0.020 |
Why?
|
India | 1 | 2012 | 2197 | 0.020 |
Why?
|
HIV Infections | 1 | 2012 | 16718 | 0.020 |
Why?
|
Chi-Square Distribution | 1 | 2012 | 3508 | 0.020 |
Why?
|
DNA, Viral | 1 | 2012 | 2225 | 0.020 |
Why?
|
Prevalence | 2 | 2012 | 15226 | 0.020 |
Why?
|
Antibodies, Monoclonal | 1 | 2022 | 9274 | 0.020 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2012 | 3870 | 0.020 |
Why?
|
Rhinitis | 1 | 2012 | 691 | 0.020 |
Why?
|
RNA, Viral | 1 | 2012 | 2902 | 0.010 |
Why?
|
Diagnosis, Differential | 1 | 2019 | 12959 | 0.010 |
Why?
|
Neoplasms | 1 | 2012 | 21683 | 0.010 |
Why?
|
Polymerase Chain Reaction | 1 | 2012 | 6171 | 0.010 |
Why?
|
United States | 2 | 2021 | 69872 | 0.010 |
Why?
|
Health Surveys | 1 | 2012 | 4037 | 0.010 |
Why?
|
Sequence Analysis, DNA | 1 | 2012 | 4803 | 0.010 |
Why?
|
Lung | 1 | 2019 | 9856 | 0.010 |
Why?
|
Biopsy | 1 | 2012 | 6756 | 0.010 |
Why?
|
Risk Factors | 2 | 2020 | 72290 | 0.010 |
Why?
|
Risk Assessment | 1 | 2020 | 23338 | 0.010 |
Why?
|
Time Factors | 1 | 2020 | 40075 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2012 | 15076 | 0.010 |
Why?
|
Prospective Studies | 1 | 2021 | 53288 | 0.010 |
Why?
|
Mutation | 1 | 2012 | 29786 | 0.000 |
Why?
|